SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ForYourEyesOnly who wrote (188)11/16/1997 12:35:00 PM
From: John McCarthy   of 569
 
Pentetration Rate %

THC

FYI -

Please note the Penetration Rate % below:

===========================================
Major P&L Assumptions:
-------------------------------------------
Synvisc (USA) Revenues :Distributor:(AHP)
===========================================
Annual AHP @ Retail $135,000,000
Annual Price (2 Treatments/yr) 1,000
BIOX % AHP .35
BIOX $ Revenues $47,250,000

Notes:
1 treatment = $500 (3 injections of Synvisc)
1 treatment = Lasts 6 months

===========================================
AHP Sales Effort:
===========================================
A - Total Osteoarthritis Population 15,600,000
B - Total Target Patient Population 7,000,000
C - 1998 Patients Treated 135,000
D - 1998 PENETRATION RATE (C/B) 1.93%

-------------------------------------------------------------------
Biomatrix (BIOX) - 1998 1st 2nd 3rd 4th 1998
===================================================================
Pr Loc Dist
-------------------------------------------------------------------
Sy3 USA (AHP) 8,000 10,000 13,000 16,000 47,000
Sy3 NON-USA (AHP) 500 800 1,200 1,600 4,100
Sy3 France (Boe Ing) 300 300 300 300 1,200
Sy3 Canada (RPR) 400 400 400 400 1,600
Sy3 Sweden (Roche) 200 200 200 200 800
Sy3 Isr./FE (Bayer AG) 100 100 100 100 400
Sy3 Italy (Recdati) 75 75 75 75 300
Sy1 England (Biox) 25 50 200 200 475
Sy1 China (Biox) 25 50 100 100 275
Sy1 Norway (Biox) 1 1 1 1 4
Sy1 Finland (Biox) 1 1 1 1 4
Sy1 Switzer (Biox) 1 1 1 1 4
Hf USA (Collagen) 0 700 700 700 2,100
Hf NON-USA (Collagen) 400 400 400 400 1,600
Hs ITAL (Far Farm) 30 30 30 30 120
Other (Biox) 200 200 200 200 800
-------------------- ------- ------- ------- ------- -------
Total Product Sales 10,258 13,308 16,908 20,308 60,782
-------------------- ------- ------- ------- ------- -------

Memo:Seq. $ 3,050 3,600 3,400
Memo:Seq. % N/A 29% 27% 20%

Memo:97 - $ 1,902 1,841 1,754 N/A
Memo:Yr/Yr % 439% 623% 864% N/A

--------------------
Milestone Fees
--------------------
AHP (from BIOX 10-Q) 0 0 0 6,000 6,000
Bayer AG 0 0 1,000 1,000 2,000
Boehringer Ingelheim 1,000 1,000 1,000 1,000 4,000
Collagen-Hylaform USA 0 5,000 0 0 5,000
-------------------- ------- ------- ------- ------- -------
Total Fees 1,000 6,000 2,000 8,000 17,000
-------------------- ------- ------- ------- ------- -------
Total Net Revenues 11,258 19,308 18,908 28,308 77,782
================== ====== ======= ======= ======= =======

Please note that in my last note to you - I made a mistake.

Product sales at 1.93% are $47.0 mil. NOT the $70.0 I spoke
of.

Regards,

John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext